TICKERNERD
Menu
XRAYXRAYHealthcare · Medical Instruments & Supplies

XRAY Stock Forecast: Dentsply Sirona, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$10
−0.76% on the day

The 18 Wall Street analysts covering Dentsply Sirona, Inc. hold a median 12-month price target of $14 — +34.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 14 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
92 / 100
Median analyst target
$14
Analysts covering
18
Revenue$898.0M−4.1% y/y
Operating income$83.0M
Net income$36.0M
Free cash flow$55.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.8%
1M
−10.4%
YTD
−9.2%
1Y
−21.3%
From 52W high
−29.3%
From 52W low
+7.7%
$10
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XRAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dentsply Sirona, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Issuance
95
Accruals
93
Volatility
83
Growth
66
Revisions
61
Quality
58
Momentum
40
Size
35

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (40): The shares have been drifting down relative to others.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XRAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XRAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18Oct 25Jan 26Apr 26Jul 26XRAYHigh $17Median $14Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
4 Buy12 Hold2 Sell
Low $11Median $14High $17

The green dot is the last close — the median target sits +34.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026BarclaysMaintainsUnderweight$9.00 → $11
29 July 2026Piper SandlerMaintainsNeutral—
29 July 2026Piper SandlerMaintainsNeutral$13 → $14
9 July 2026BMO CapitalInitiatesMarket Perform—
4 June 2026BarclaysMaintainsUnderweight—
7 May 2026UBSMaintainsBuy—
6 May 2026MizuhoMaintainsNeutral—
15 Apr 2026CitigroupInitiatesSell—
2 Mar 2026Barrington ResearchMaintainsOutperform—
2 Mar 2026MizuhoMaintainsNeutral—
27 Feb 2026BairdMaintainsNeutral—
27 Feb 2026Evercore ISI GroupMaintainsIn-Line—
27 Feb 2026Wells FargoMaintainsEqual-Weight—
19 Feb 2026B of A SecuritiesUpgradeBuy—
3 Feb 2026UBSMaintainsBuy—
20 Jan 2026MizuhoMaintainsNeutral—
5 Jan 2026Barrington ResearchMaintainsOutperform—
16 Dec 2025BairdMaintainsNeutral—
16 Dec 2025Barrington ResearchMaintainsOutperform—
9 Dec 2025BarclaysInitiatesUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XRAY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XRAY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Dentsply Sirona, Inc. returned −21.3% against +17.0% for the S&P 500, dividends included.

XRAY vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26XRAYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XRAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.8%
Analysts raising
12
Analysts cutting
5
Fundamentals

Dentsply Sirona, Inc. (XRAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
1.6×

Cheaper than 53% of US stocks

EV / EBITDA
7.9×

Cheaper than 45% of US stocks

Growth & margins
Revenue growth (YoY)
−4.1%

Higher than 21% of US stocks

Earnings growth (YoY)
−4.1%

Higher than 31% of US stocks

Gross margin
54.9%

Higher than 68% of US stocks

Operating margin
9.2%

Higher than 63% of US stocks

Net margin
−15.0%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−33.0%

Higher than 26% of US stocks

Return on assets
2.0%

Higher than 58% of US stocks

Dividend yield
6.1%

Higher than 86% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dentsply Sirona, Inc. (XRAY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dentsply Sirona, Inc. has a market value of $2.1B and an enterprise value of $4.2B.

  • Revenue in the twelve months to 30 June 2026: $3.6B. The latest quarter shrank 4.1% year on year.

  • Net income over the same four quarters: −$547.0M, a −15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.75.

  • Free cash flow in the twelve months to 30 June 2026: $143.0M, after $176.0M of capital spending.

  • Dentsply Sirona, Inc. spent $96.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 199.2M.

  • Trailing P/E: −3.5×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 6.12%, paying out 29% of earnings.

  • Dentsply Sirona, Inc. employs 14,000 people — $260K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

XRAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
XRAYDentsply Sirona, Inc.$2.1B
92
LMATLeMaitre Vascular, Inc.$1.8B
69
BLFSBioLife Solutions, Inc.$1.7B
91
ATRCAtriCure, Inc.$2.8B
94
AZTAAzenta, Inc.$1.5B
81
KMTSKestra Medical Technologies Ltd.$1.4B
22
WRBYWarby Parker, Inc.$3.1B
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dentsply Sirona, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XRAY news & analysis

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

Zacks Investment Research · 8 Sept 2026neutral

XRAY beat Q2 earnings and revenue estimates while holding 2026 guidance and improving cash flow, though falling sales and margin pressure persist. The company's recovery outlook remains clouded by these headwinds.

Why it matters — XRAY watchers would care because the earnings beat and steady guidance offer some stability, but ongoing sales declines and margin pressure indicate the company's recovery is not yet complete.

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 7 Sept 2026negative

A law firm has issued a notice suggesting that Dentsply Sirona insiders may have breached their fiduciary duties to shareholders. The firm is encouraging shareholders to contact it to discuss their rights and legal options on a contingent-fee basis.

Why it matters — The notice raises potential legal and governance concerns regarding Dentsply Sirona insiders that XRAY shareholders may want to monitor.

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Dentsply Sirona announced it will participate in the Baird 2026 Global Healthcare Conference, with management scheduled to present on September 15, 2026, at 11:25 a.m. ET.

Why it matters — XRAY watchers would care because the scheduled presentation gives investors an opportunity to hear company management's outlook at a major healthcare industry gathering.

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

Schwab Network · 2 Sept 2026neutral

Thomas Hayes on Schwab Network presented a contrarian view advocating for bond purchases, citing "950 billion reasons," the seasonality effect, a crowded AI trade, geopolitical complexity, and rising crude oil as factors he expects to support a lasting bond rally. He also mentioned PFE and XRAY as buy opportunities.

Why it matters — Hayes explicitly names XRAY as a buy opportunity, so XRAY watchers may be interested in his reasoning on the macro conditions he believes support that view.

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

PRNewsWire · 19 Aug 2026positive

Wellspect HealthCare, a Dentsply Sirona brand, announced the U.S. launch of the Surity™ Urinary Management System, an at-home urine collection device for people living with urinary incontinence. The launch completes the full Surity™ portfolio in the U.S., following the earlier introduction of the Surity™ Female and Male External Catheters.

Why it matters — The product launch expands Dentsply Sirona's urology portfolio in the U.S. market, broadening its offering for the urinary incontinence segment.

FAQ

Frequently asked questions about XRAY stock

What is the XRAY stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Dentsply Sirona, Inc. have a median 12-month price target of $14, with estimates ranging from $11 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XRAY stock a buy right now?

Of the 18 analysts covering Dentsply Sirona, Inc., 4 rate it a Buy, 12 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Dentsply Sirona, Inc. 92 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XRAY?

As at 14 Sept 2026, Dentsply Sirona, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will XRAY stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +34.9% from the last close, and Ticker Nerd's factor model ranks Dentsply Sirona, Inc. 92 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XRAY stock forecast for 2030?

No analyst covering Dentsply Sirona, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XRAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $17 over the next 12 months.

How has XRAY stock performed over the past year?

Dentsply Sirona, Inc. returned -21.3% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dentsply Sirona, Inc. do?

Dentsply Sirona Inc. is a global dental products and technologies company that serves dental practices, clinics, laboratories, and distributors worldwide.

What is the latest news on XRAY?

The most recent item we track (Zacks Investment Research, 8 Sept 2026): "XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure". XRAY beat Q2 earnings and revenue estimates while holding 2026 guidance and improving cash flow, though falling sales and margin pressure persist. The company's recovery outlook remains clouded by these headwinds.

Company

About Dentsply Sirona, Inc.

Dentsply Sirona Inc. is a global dental products and technologies company that serves dental practices, clinics, laboratories, and distributors worldwide. The company develops, manufactures, and markets a broad portfolio that includes dental consumables, restorative materials, digital imaging systems, CAD/CAM restoration platforms, treatment centers, handpieces, hygiene systems, orthodontic and implant products, and specialty solutions for endodontics and other oral care applications. Dentsply Sirona also provides workflow-oriented technologies designed to support diagnosis, treatment planning, and chairside procedures across modern dental settings. Headquartered in Charlotte, North Carolina, Dentsply Sirona is a major supplier in the professional dental market, combining equipment, software-enabled tools, and everyday consumables to support clinical efficiency and patient care.

CEO Mr. Daniel T. Scavilla · 14,000 employees · United States · https://www.dentsplysirona.com